Do SGLT2 Inhibitors Improve Cardio-Renal Outcomes in Patients With Type II Diabetes Mellitus: A Systematic Review

Sahithi Reddy Kalluri 1, Tinaz H. Bhutta 1, Hanan Hannooodee 1, Mahmoud Al Khalili 1, Nyein Wint Yee Theik 1, Oluwatimilehin E. Raji 2, Priya Shenwai 1, Rutul Shah 1, Safeera Khan 1

1. Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 2. Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA

Corresponding author: Sahithi Reddy Kalluri, sahithireddykalluri@gmail.com

Abstract

Diabetes mellitus (DM) is associated with dreadful changes in the cardiovascular and renal systems, causing increased morbidity and mortality. Sodium-glucose cotransport-2 (SGLT2) inhibitors belong to the oral hypoglycemic group of drugs believed to reduce these events by various mechanisms in DM. We performed a systematic review to determine the effectiveness of SGLT2 inhibitors in reducing cardiovascular and renal complications and address safety concerns in participants with type 2 diabetes mellitus (T2DM).

We explored PubMed, PubMed Central, Medical Literature Analysis and Retrieval System Online (MEDLINE), Cochrane library, and ResearchGate for randomized controlled trials and observational studies done on the advantages of SGLT2 inhibitors in the prevention or reduction of worsening cardiovascular and renal changes in T2DM. Studies were screened for the quality assessment using the Cochrane risk-of-bias assessment tool and Newcastle-Ottawa scale. We screened 5615 articles, out of which 22 articles with 7,02,977 diabetes mellitus patients treated with SGLT2 inhibitors were used for the systematic review after meticulously filtering articles based on inclusion and exclusion criteria. The trials included one of the following drugs - empagliflozin, dapagliflozin, canagliflozin, and luseogliflozin. SGLT2 inhibitors significantly reduced the risk of heart failure (HF), frequency of hospitalizations due to HF, all-cause mortality, cardiovascular mortality, and nonfatal myocardial infarction. Renal outcomes showed a significant lowering of risk of acute kidney failure, progression of chronic kidney disease, renal mortality, and improvement in urinary albumin creatinine ratio. We noticed an initial worsening of the estimated glomerular filtration rate followed by stabilizing and reaching the baseline on long-term treatment, especially in end-stage renal failure patients.

The review showed that SGLT2 inhibitors have adverse reactions similar to that of a placebo, with a slight increase in treatable genital mycotic and urinary tract infections but no evidence of diabetic ketoacidosis, fractures, and amputations. According to the available data, SGLT2 inhibitors can significantly prevent or reduce cardiovascular diseases and kidney abnormalities in patients with type 2 diabetes mellitus with tolerable safety outcomes.

Introduction And Background

Centre for Disease Control and Prevention (CDC) data states that as of 2018, diabetes mellitus (DM) in the USA is prevalent in approximately 10.5% of the population, with serious microvascular and macrovascular complications [1]. Significant microvascular changes cause chronic kidney disease (CKD) with a prevalence of 45.2% in type 2 diabetes mellitus (T2DM) cases [2]. Cardiovascular disease (CVD) is also a major complication affecting 32.2% of DM type II patients and the cause of death in 50.3% of patients [3].

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are approved for glucose lowering in patients with T2DM along with reducing reno-vascular complications and enhancing weight loss. The mechanism of action of SGLT2 inhibitors is to promote glucose excretion in urine by blocking glucose and sodium reuptake in the early proximal renal tubule and thereby reduce blood glucose levels [4]. The other beneficial effect of SGLT2 inhibitors is their promotion of sodium excretion in urine that causes osmotic diuresis and reduced blood pressure [4,5]. These drugs reduce endogenous glyceral-derived hepatic gluconeogenesis from visceral adipose tissue causing weight loss [6]. One of the renal protective mechanisms of SGLT2 inhibitors is in albuminuria where it reduces intra-glomerular pressure and prevents subsequent tubular cell injury [7]. These pleiotropic effects have reduced cardiovascular events and preserved kidney functions. According to American Diabetes Association (ADA), these drugs are currently recommended as supplement treatment in T2DM patients with high risk or established CVD, established CKD, or heart failure (HF) independent of hemoglobin A1C (HbA1C) values of...
the patients [8].

There is no sufficient evidence showing glucose-lowering medications reduce the risk of cardiovascular disorders or mortality in T2DM patients. A moderate cardiovascular benefit may be observed after long-term treatment and follow-up as noticed in a few studies [9]. Besides, there may be adverse cardiovascular outcomes with strict glycemic control or due to the use of SGLT2 inhibitors [10].

SGLT2 inhibitors affect the kidney; they might pose a threat to patients with renal disorders. The function of the drug depends on the renal function filtration capacity of the kidney: as kidney function declines, the efficacy of the drug declined [11]. The risk-benefit ratio should be assessed before starting treatment with these drugs. SGLT2 inhibitors are not currently advised in chronic kidney disease patients with an estimated glomerular filtration rate (eGFR) of <45mL/min/1.73m2 for empagliflozin and canagliflozin, and <60mL/min/1.73m2 for dapagliflozin [12,13,14]. This raises queries about the effects on efficacy to improve cardiovascular, renal, and safety outcomes in people with reduced eGFR.

Hence, we started a systematic review of randomized controlled trials and observational trials to understand better the efficiency of SGLT2 inhibitors in providing protection from cardiovascular disorders and preventing renal adverse outcomes in individuals with T2DM.

**Review**

**Methods**

We conducted a systematic review as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15]. Figure 1 depicts the search process in the form of a PRISMA flow diagram.

![FIGURE 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram](image_url)

**Data Source and Strategy**

We systematically searched for relevant articles indexed at PubMed, PubMed Central, MEDLINE, Cochrane library, and ResearchGate. We explored the databases using keywords and the medical subject headings (MeSH) strategy to maximize the number of articles.

We used the following MeSH strategy to search for relevant papers: ("Sodium-Glucose Transporter 2 Inhibitors/administration and dosage"[MeSH] OR "Sodium-Glucose Transporter 2 Inhibitors/adverse effects"[MeSH] OR "Sodium-Glucose Transporter 2 Inhibitors/therapeutic use"[MeSH] OR "Sodium-Glucose Transporter 2 Inhibitors/toxicity"[MeSH]) OR ("Canagliflozin/administration and dosage"[MeSH] OR "Canagliflozin/adverse effects"[MeSH] OR "Canagliflozin/therapeutic use"[MeSH] OR "Canagliflozin/toxicity"[MeSH]) OR ("Sodium-Glucose Transporter 2 Inhibitors"[Pharmacological Action]) AND ("Diabetes Mellitus, Type 2/drug therapy"[MeSH] OR "Diabetes Mellitus, Type 2/therapy"[MeSH]) AND ("Heart Failure/drug therapy"[MeSH] OR "Heart Failure/prevention and control"[MeSH] OR "Heart Failure/therapy"[MeSH]) AND
Inclusion and Exclusion Criteria

We included peer-reviewed randomized controlled trials (RCTs) and observational studies relevant to the research question published in the English Language in the past 10 years that focus on the adult and geriatric population (>18 years).

We excluded articles published in other languages, grey literature, books, case series, case reports, unpublished literature, and the pediatric population.

Screening and Quality/Bias Assessment

We assessed 37 studies for quality using standardized quality assessment tools, and 33 articles qualified for the quality appraisal. The following tools were used:

1. Randomized controlled trials: Cochrane risk-of-bias assessment tool.
2. Observational studies: Newcastle-Ottawa scale

Results

Our initial search yielded 5615 articles. After the duplicates (n=2523) and those that weren’t available with full text (n=1236) were removed, we were left with 1856 articles that were screened by title and inclusion/exclusion criteria by automation. Following this, 1724 non-relevant articles were excluded. Out of the remaining 132 articles, 39 articles could not be retrieved. Abstracts and full text of the 93 relevant articles that remained were thoroughly read, and 52 were excluded after inclusion criteria were applied. Lastly, after meticulous quality assessment, 19 more articles were excluded.

Our review article includes 22 articles with 7,02,977 diabetes mellitus patients from 18 randomized control trials, and four observational studies that included one of the following drugs - empagliflozin, dapagliflozin, canagliflozin, and luseogliflozin. SGLT2 inhibitors significantly reduced the risk of HF, frequency of hospitalizations due to HF, all-cause mortality, cardiovascular (CV) mortality, and nonfatal myocardial infarction. Renal outcomes showed a significant lowering of risk of acute kidney failure, progression of CKD, renal mortality, and improvement in urinary albumin creatinine ratio. Studies showed that adverse reactions in both SGLT2 inhibitors and placebo groups were identical, with a slight increase in treatable genital mycotic and urinary tract infections in the treatment group. There was no evidence of diabetic ketoacidosis, fractures, and amputations.

Discussion

SGLT2 inhibitors, when used in patients with diabetes mellitus, can reduce the risk for cardiac and renal abnormalities significantly but with a debatable safety profile.

Cardio-Protective Profile of SGLT2 Inhibitors

With cardiovascular disorders being an important cause of mortality in T2DM patients, the efficacy of the SGLT2 inhibitor to reduce this risk is assessed. An international study by Kosiborod et al. conducted in patients with T2DM from the Asia Pacific, the Middle East, and North America, comparing SGLT2 inhibitors and other glucose-lowering drugs, showed a significant reduction in hospitalization due to HF, the incidence of myocardial infarction (MI), and all-cause mortality [16]. A randomized control trial by Zinman et al. on 7020 patients found that using the empagliflozin drug lowered the risk of death from cardiovascular complications in comparison to the placebo [17]. Fitchett et al. stated that empagliflozin could reduce the risk of recurrence and mortality of MI/stroke in patients with type 2 diabetes mellitus but the results were insignificant [18]. An overview of the cardiac-related advantages of SGLT2 inhibitors in T2DM patients is given in Figure 2.
FIGURE 2: Describes the uses of SGLT2 inhibitors in type 2 diabetes mellitus patients with heart disorders

SGLT2: Sodium-glucose cotransporter-2 inhibitors; HF: Heart failure; BMI: Body mass index; BP: Blood pressure

Post hoc analysis of the empagliflozin cardiovascular outcome event trial in type 2 diabetes mellitus patients-removing excess glucose (EMPA-REG) done in 2020 by Kaku et al., studied the effect of empagliflozin vs. placebo in reduction of seven cardiovascular (CV) risk factors. Participants were classified into three subgroups based on their risk factor score of zero to three, four to five, or six to seven of the following seven goals for CV risk factor control at baseline: (1) HbA1C <7.5%; (2) low density lipoprotein cholesterol <100mg/dL or statin use; (3) systolic blood pressure (SBP) <140mmHg and diastolic blood pressure (DBP) <90mmHg; (4) use of angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker; (5) normoalbuminuria; (6) aspirin use; (7) non-smoking status. Results showed that 56% had achieved four or five goals at the time of the study, 31% had met six, and only 6.7% had achieved all seven goals [19].

Kaku et al. discussed the effect of empagliflozin in 1517 Asian patients with CV risk factors and T2DM; the study showed that three-point major adverse cardiac events (MACE), four-point MACE, hospitalization for HF, the composite of HF hospitalization or CV death were significantly decreased and were consistent with the other studies [20].

A recent RCT by Phrommintikul et al. comparing dapagliflozin and vildagliptin showed a significant reduction in body weight and body mass index (BMI) in the dapagliflozin group [21]. In contrast, a significant increase in weight was observed in the vildagliptin. Systolic blood pressure was significantly decreased in the dapagliflozin group but did not change in the vildagliptin group. There was no significant change in diastolic BP, heart rate, eGFR, N-terminal pro-brain natriuretic peptide (NT-proBNP) in either group. The mean hemoglobin was significantly increased in the dapagliflozin group. In contrast, no change was seen in the vildagliptin group. High-sensitivity Troponin T (Hs-TnT) significantly decreased in the dapagliflozin group, though a non-significant increase in Hs-TnT was noticed in the other group [21].

A large CANVAS study program by Rådholm et al. was conducted on 10,142 patients with T2DM. In this study, compared to the placebo, canagliflozin reduced the risk of cardiovascular death or hospitalization due to heart failure significantly in patients with a previous history of HF, whereas in patients with no history of HF at baseline, the results showed p-value>0.05 after a mean follow-up time of 188.2 weeks [22]. Table 1 shows the synopsis of 10 articles depicting the cardiovascular effects of SGLT2 inhibitors.
| Publication          | Year | Drug         | Patients | Type of Study | Purpose                                                                 | Results/Conclusion                                                                 |
|---------------------|------|--------------|----------|---------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Kosiborod et al. [16] | 2018 | All          | 235,064  | RCT           | Outlined CV outcomes in patients using SGLT2i and OGLDs across six countries | SGLT2i group showed a reduced risk of death, HHF, MI vs. OGLDs                      |
| Zinman et al. [17]  | 2017 | Empagliflozin| 7020     | RCT           | Effects on cardiovascular morbidity and mortality in T2DM                | Lower rate of death from cardiovascular causes, nonfetal MI, or nonfetal stroke    |
| Fitchett et al [18] | 2019 | Empagliflozin| 10,773   | RCT           | Examined empagliflozin effects on 3-point MACE, CVD and all-cause death, and HHF across various cardiovascular risk groups | Reductions in CV outcomes and mortality were similar across the spectrum of cardiovascular risk |
| Inzucchi et al. [19] | 2020 | Empagliflozin| 7020     | RCT           | To identify the association of CV risk factor reduction with CV benefits of empagliflozin | The cardioprotective effect was consistent regardless of multiple baseline risk factor control |
| Kaku et al. [20]    | 2017 | Empagliflozin| 7,020    | RCT           | Effects of empagliflozin in patients of Asian race                      | MACE, all-cause mortality, and HF outcomes in Asian patients were congruous with the worldwide population |
| Phrommintikul et al. [21] | 2019 | Dapagliflozin| 49       | RCT           | Investigate cardiometabolic effects of dapagliflozin and vildagliptin in T2DM patients with CAD | More benefits in cardiovascular outcomes were observed in dapagliflozin compared to vildagliptin |
| Radholm et al. [22] | 2018 | Canagliflozin| 10,142   | RCT           | Identify the advantages of canagliflozin on HF and cardiovascular death overall, in those with and without a history of HF | The benefit of reduced mortality and HHF may be higher in patients with a past history of HF |
| Mahaffey et al. [23] | 2019 | Canagliflozin| 4401     | RCT           | Effect of canagliflozin to reduce adverse CV outcomes in T2DM and CKD patients with or without previous CVD | Canagliflozin significantly decreased MACE and kidney failure, including the participants with no previous CVD |
| Bohm et al. [24]    | 2020 | Empagliflozin| 7,020    | Observational | Explore CV and renal outcomes in patients with vs. without AF at baseline | Empagliflozin lowered HF-related and renal events, irrespective of AF status |
| Chen HY et al. [25] | 2020 | All          | 399,810  | Observational | Identify the link between SGLT2 inhibitors and the risk of arrhythmias    | SGLT2 inhibitors were associated with a reduced risk of all-cause mortality and new-onset arrhythmias |

**TABLE 1: Summary of the articles which demonstrate the efficacy of SGLT2 inhibitors in T2DM patients to improve cardiac abnormalities.**

T2DM: Type 2 diabetes mellitus; CV: Cardiovascular; SGLT2i: Sodium-glucose cotransporter-2 inhibitors; HHF: Hospitalization due to heart failure; MI: Myocardial infarction; MACE: Major adverse cardiac effects; CAD: Coronary artery disease; CKD: Chronic kidney disease; CVD: Cardiovascular disease; AF: Atrial fibrillation
included in the secondary prevention group. Surprisingly, canagliflozin reduced major cardiovascular events in both groups. These results were consistent in those with risk of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure in both the primary and secondary prevention groups [23].

A retrospective analysis by Böhm et al. was done on the effect of empagliflozin on reducing cardiac adverse events in patients with T2DM with and without atrial fibrillation (AF). Increased cardiac abnormalities were noticed in the AF group at baseline, but empagliflozin consistently reduced the cardiac events in both groups significantly by reducing the plasma volume, load reduction on ventricles, and by enhancing cardiac energy. The event rates of nephropathy were similar in both groups, but the drug reduced incidence and progression of nephropathy in patients with AF vs. without AF by increasing sodium and fluid excretion causing a reduction in volume overload on kidneys [24]. Another large longitudinal study by Chen et al. on 399,810 patients with T2DM demonstrated that SGLT2 inhibitors were linked to significantly reduce risk of all-cause mortality and new-onset arrhythmias compared to participants that were not on any SGLT2 inhibitors [25].

**Renal-Protective Profile of SGLT-2 Inhibitors**

Reduction in urinary albumin creatinine ratio (UACR) is believed to be an important mechanism of action of SGLT2 inhibitors in improving renal outcomes. Oshima et al. stated that canagliflozin at the end of 26 weeks reduced geometric mean UACR by 51%, and also reduced the risk of progression in UACR from non-nephrotic to nephrotic-range albuminuria and regression in UACR stage from macroalbuminuria to micro or normoalbuminuria compared with placebo. These early albumin changes independently improve renal and cardiac disorders when used for the long term in participants with T2DM with CKD [26]. Figure 3 gives a brief outline of the usage of SGLT2 inhibitors to improve renal function.

**FIGURE 3: Emphasizes the indication, advantage, and adverse effects of SGLT2 inhibitors when used to improve renal function.**

CKD: Chronic kidney disease; eGFR: Estimated glomerular filtration rate

Heerspink et al., in a trial on 4304 CKD patients, examined the efficacy of dapagliflozin, of which 32.5% did not have type 2 diabetes. Results showed a significant reduction in risk of constant downslope in the eGFR by at least 50%, end-stage kidney disease, or mortality from renal or cardiovascular causes with dapagliflozin compared to placebo, with results being similar in patients with or without T2DM [27]. Canagliflozin and renal events in diabetes with established nephropathy clinical evaluation (CREDENCE) trial is another large study conducted in 34 countries, which stated that the rate of the end-stage kidney disease progression, doubling of the serum creatinine level, or renal or cardiovascular death was significantly lower in the canagliflozin group than in the placebo group, with 50% lower relative risk with p-value=0.00001 [28]. A Japanese study on the effects of canagliflozin in patients with T2DM and HF showed improvements in renal function after 12 months after the initiation of treatment. This trial by Sezai et al. concluded that SGLT2 inhibitors could be used as first-line treatment in heart failure for T2DM patients with preserved ejection fraction [29].

Although studies showed improvement in renal function, long-term trials with frequent follow-up showed
fluctuating eGFR results. Wanner et al. noticed significant relative risk reduction in incidence or worsening nephropathy, macroalbuminuria, doubling of creatinine in patients treated with empagliflozin vs. placebo groups. But no difference in the rate of incident albuminuria in both the groups. They observed a significant short-term reduction in eGFR in empagliflozin groups, compared with a small increase in the placebo group from baseline to week four (period one). After continued administration (period two), stabilization of eGFR in the SGLT2 group and progressive decline in placebo. Drugs were withdrawn during the last week of treatment to follow-up (period three), a significant increase in eGFR with both doses of empagliflozin. However, a small decrease in the placebo group was identified [30]. Similar findings were also discussed by a randomised prospective Japanese study on the reno-protective function of canagliflozin in T2DM with CKD patients, i.e., reduction in eGFR from baseline for four weeks but later improved to reach the baseline values by 26 weeks in canagliflozin group. Significant reduction in urinary albumin-creatinine ratio, urinary liver-type free acid-binding protein, N-acetyl-β-d-glucosaminidase, and β2-microglobulin levels was also observed in the treatment group vs. control group [31]. Eight studies that looked into the kidney protective action of SGLT2 inhibitors in T2DM patients are summarized in Table 2.

| Publication | Year | Drug | Study Population | Type of Study | Purpose | Results/Conclusion |
|-------------|------|------|------------------|--------------|---------|--------------------|
| Oshima et al. [26] | 2019 | Canagliflozin | 4401 | RCT | To Identify the association between early changes in albuminuria and cardiorenal abnormalities | Early reductions in albuminuria were independently associated with long-term benefits in kidney and cardiovascular outcomes |
| Heerspink et al. [27] | 2020 | Dapagliflozin | 4304 | RCT | Effect of the dapagliflozin on renal and cardiovascular events in CKD patients with and without diabetes | Improvement in renal function and reduced mortality among patients with CKD, irrespective of DM status |
| Perkovic et al. [28] | 2019 | Canagliflozin | 4401 | RCT | To assess the renal outcomes in T2DM and CKD on long term use of SGLT2 inhibitors | Lower risk of kidney failure and cardiovascular events in the canagliflozin group |
| Sezai et al. [29] | 2019 | Canagliflozin | 35 | Clinical Trial | To demonstrate the cardioprotective function in T2DM and chronic heart patients | Canagliflozin improved oxidative stress, diastolic function, endothelial function, displayed cardiac and renal protective effects |
| Wanner et al. [30] | 2016 | Empagliflozin | 7020 | RCT | To determine the long-term renal effects of empagliflozin | In T2DM with high cardiovascular risk, empagliflozin showed delayed progression of CKD and low rates of renal events |
| Takashima et al. [31] | 2018 | Canagliflozin | 40 | RCT | To evaluate the renoprotective effects, albuminuria- lowering effects of canagliflozin, in Japanese in T2DM with CKD | Canagliflozin was associated with a slower progression of kidney disease. Reduction in albuminuria and tubulointerstitial markers. |
| Ito et al. [32] | 2021 | Luseogliflozin | 238 | Observational | The safety and efficacy of luseogliflozin in Japanese patients | Preserves the renal function in the medium term in patients with T2DM and renal impairment |
| Pastemak et al. [33] | 2020 | All | 29,887 | Observational | To assess the association between SGLT2 and DPP-4i to lower the risk of serious renal events | SGLT2 inhibitors were associated with a significantly reduced risk of serious renal events |

**TABLE 2: Outlines the articles describing the function of SGLT2 inhibitors to improve renal outcomes.**

T2DM: Type 2 diabetes mellitus; CKD: Chronic kidney disease; SGLT2i: Sodium-glucose cotransporter-2 inhibitors; DPP-4i: Dipeptidyl peptidase 4 inhibitors

In a retrospective study by Ito et al., patients were divided into three groups based on eGFR values to identify any variations between the groups, with a follow-up of 12 months before and after administration of luseogliflozin. Results showed preserved eGFR in patients with low eGFR group after administration. Still,
they gradually decreased before the administration in the present study. In contrast, there was a slight decrease in eGFR in normal or high eGFR groups after the initiation of SGLT2 inhibitor treatment [32].

A large cohort study on 59,772 patients was done by Pasternak et al. to study and compare SGLT2 inhibitors. Dipeptidyl peptidase 4 (DPP-4) inhibitors showed the incidence of renal events was significantly lower in the SGLT2 group, which was more during the initial two years of follow-up. SGLT2 inhibitors were also associated with a significantly low risk of renal replacement therapy and hospital admission from renal events vs. DPP-4 inhibitors [33].

Safety Profile of SGLT-2 Inhibitors

SGLT2 inhibitors are well tolerated with a lower number but with serious adverse reactions. A 52-week double-blinded randomized control study by Damman et al. showed that mild to moderate intensity recurrent genital infections, single episodes of lower urinary tract infections (UTI) that responded to standard treatment were seen in greater proportions in the dapagliflozin vs. glipizide group. No events of pyelonephritis, diabetic ketoacidosis, and elevated liver enzymes were noted in the SGLT2 inhibitors group [34]. Another pilot study on empagliflozin also showed no difference in cases of UTI compared to placebo [35]. Upon further review, four studies were identified that discussed the adverse reactions of SGLT2 inhibitors, and these are summarized in Table 3.

| Publication          | Year | Drug       | Population | Study type | Purpose                                                                 | Results/ conclusion                                                                 |
|----------------------|------|------------|------------|------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Nauck et al. [34]    | 2011 | Dapagliflozin | 814        | RCT        | Comparison of the efficacy, safety, and tolerability of dapagliflozin vs. sulfonylurea glipizide in T2DM | Dapagliflozin reduced weight and produced less hypoglycemia than glipizide in T2DM with similar efficacy |
| Damman et al. [35]   | 2020 | Empagliflozin | 80         | RCT        | Safety and clinical efficacy of SGLT2 inhibitors in patients with acute decompensated HF | Showed no difference in cases of UTI compared to placebo |
| Fioretto et al. [36] | 2018 | Dapagliflozin | 321        | clinical Trial | To assess the efficacy and safety of dapagliflozin 10mg vs. placebo in patients with T2DM and moderate renal impairment (CKD 3A) | No increase in adverse events, no bone fractures, amputations, or DKA were reported with dapagliflozin vs. placebo |
| Jardine et al. [37]  | 2020 | Canagliflozin | 4401       | RCT        | Described efficacy and safety of canagliflozin across various eGFR groups | No harmful adverse effects, amputations, and fractures. Results were consistent among eGFR subgroups. |

The study to evaluate the effect of dapagliflozin on blood glucose level and renal safety in patients with type 2 diabetes (DERIVE) reported no difference in percentages of genital infections, and UTI in dapagliflozin compared to the placebo group. However, the drug caused worsening of eGFR/renal failure for the initial four weeks and returned to baseline within 27 weeks. In contrast, hypoglycemia was rare in both the treatment and placebo groups. Occasionally hypotension, dehydration, hypovolemia was identified [36]. Jardine et al. stated that rates of fractures and amputations were similar in both canagliflozin and placebo groups irrespective of eGFR. Whereas the canagliflozin group showed significantly fewer cases of volume depletion and osmotic diuresis, variations were observed among different eGFR subgroups [37]. Figure 4 represents the cardiac and renal benefits that exceed the adverse effects of SGLT2 inhibitors in T2DM patients.
Limitations
Although our systematic review included multiple RCTs and observational studies which showed the significant role of SGLT2 inhibitors in reducing cardiac and renal outcomes with a good safety profile, there are certain limitations. One, the heterogeneity in the characteristics of the population, clinical setting of the study and follow-up duration of the studies included. Two, there are not enough studies regarding the cardio-renal protective role in the non-diabetic population. Three, a low cardiac risk population accounts for a significant proportion that was not included in these trials. Finally, data about the eGFR fluctuations and efficacy of SGLT2 inhibitors in CKD stage 3/4 should be addressed. The current large trials such as the study of heart and kidney protection with empagliflozin (EMPA-KIDNEY), Semaglutide cardio-vascular outcomes trial in patients with type 2 diabetes (SOUL), and the study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW) may be necessary to provide better insight into these constraints.

Conclusions
This systematic review is performed to consolidate the evidence of sodium-glucose cotransport-2 (SGLT2) inhibitors to reduce cardiovascular and renal complications and adverse effects in diabetes mellitus from 22 randomized control trials and observational studies. SGLT2 inhibitors significantly lowered all-cause and cardiovascular mortality, myocardial infarction, hospitalizations due to heart failure, the risk for new-onset arrhythmias, kidney failure, incidence or worsening nephropathy, macroalbuminuria, lower body weight, blood pressure with a slight increase in the risk of UTI, and genital infections in T2DM patients.

This data serves as an overview for physicians regarding various studies performed. These drugs can be used in T2DM patients with cardiovascular complications to reduce worsening in low to high-risk patients. But caution is required in CKD patients, with close monitoring of eGFR. More studies are required to provide evidence of the efficacy of SGLT2 inhibitors in non-diabetic patients with cardiac or renal diseases. Larger sample sizes and long-term RCTs, and observational studies are needed to know the prophylactic benefits of using SGLT2 inhibitors in de novo diabetes mellitus patients with no heart or kidney complications.

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might

FIGURE 4: Denotes that the benefits of SGLT2 inhibitors out-weigh the risk of using the drug.
have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. National Diabetes Statistics Report 2020. Estimates of Diabetes and Its Burden in the United States . (2020). Accessed: April 20, 2021: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.

2. Bailey RA, Wang Y, Zhu V, Runpow MF: Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on kidney disease: improving global outcomes (KDIGO) staging. BMC Res Notes. 2014, 7:415. 10.1186/1756-0500-7-415.

3. Einnstron TR, Arc A, Ludwig G, Panton UE: Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018, 17:83. 10.1186/s12933-018-0728-6.

4. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ: Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016, 134:752-772. 10.1161/CIRCULATIONAHA.116.021887.

5. Heerspink HJ, Kosiborod M, Inzucchi SE, Cherney DZ: Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018, 94:26e-39. 10.1016/j.kint.2017.12.027.

6. Neelander JI, de Albuquerque Rocha N, Hughes C, Ayers CR, Malloy CR, Lin ES: Effects of empagliflozin treatment on glycemic control in adults with obesity: a randomized clinical trial. Obesity (Silver Spring). 2020, 28:1254-1262. 10.1002/oby.22854.

7. Dekkers CC, Petrykis S, Leverman GD, Cherney DZ, Gansevoort RT, Heerspink HJ: Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018, 20:1988-1993. 10.1111/dob.13301.

8. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021, 44:S11-S124. 10.2337/dci20-0060.

10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008, 359:1577-1589. 10.1056/NEJMoa0806470.

11. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM: Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015, 3:556-566. 10.1016/S2213-8587(15)00044-3.

12. Petrykis S, Sjöström CD, Graseby PJ, Xu J, Persson F, Heerspink HJ: Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol. 2017, 12:751-759. 10.2215/CJN.1080916.

13. Scheen AJ: Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015, 54:691-708. 10.1007/s40262-015-0264-4.

14. Cherney DZ, Cooper ME, Tikkkanen I, et al.: Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018, 95:251-244. 10.1016/j.kint.2017.06.017.

15. Neuen BL, Ohkuma T, Neal B, et al.: Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018, 138:1537-1550. 10.1161/CIRCULATIONAHA.118.035901.

16. Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021, 10:89.

17. Kosiborod M, Lam CS, Koshaka S, et al.: Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018, 71:2628-2639. 10.1016/j.jacc.2018.03.009.

18. Zinman B, Wanner C, Lachin JM, et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-2128. 10.1056/NEJMoa1504721.

19. Fitchett D, Inzucchi SE, Cannon CP, et al.: Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019, 139:S1584-S1595. 10.1161/CIRCULATIONAHA.118.057778.

20. Inzucchi SE, Khunti K, Fitchett DH, et al.: Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME trial. J Clin Endocrinol Metab. 2020, 105:5025-5035. 10.1210/clinems/goa321.

21. Kaku K, Lee J, Matthews M, Kaspers S, George J, Woerle HJ: Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease - results from EMPA-REG OUTCOME®. Circ J. 2017, 81:227-234. 10.1253/circj.CJ-16-1148.

22. Phrommitikul A, Wongcharoen W, Kumfu S, Jaivongkarn T, Gunapann S, Chattipakorn S, Chattipakorn N: Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study. Br J Clin Pharmacol. 2019, 85:1537-1547. 10.1111/bcp.13965.

23. Radholm K, Figtger G, Perkovic V, et al.: Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018, 138:458-468. 10.1161/CIRCULATIONAHA.117.032422.

24. Mahaffey KW, Jardine MJ, Bompoint S, et al.: Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019, 140:739-750. 10.1161/CIRCULATIONAHA.119.042007.

25. Böhm M, Slavik J, Bruckmann M, et al.: Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. Eur J Heart Fail. 2020, 22:126-135. 10.1002/ejhf.1663.

26. Chen HY, Huang JY, Siao WZ, Jong GP: The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. Cardiovasc Diabetol. 2020, 19:75. 10.1186/s12933-020-01048-x.

27. Oshima M, Neuen BL, Li J, et al.: Early change in albuminuria with canagliflozin predicts kidney and
cardiovascular outcomes: a post hoc analysis from the CREDEnCE trial. J Am Soc Nephrol. 2020, 31:2925-2936. 10.1681/ASN.2020050723

27. Heerspink HJ, Sjöström CD, Jong N, et al.: Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J. 2021, 42:1216-1227. 10.1093/eurheartj/ehab694

28. Perkovic V, Jardine MJ, Neil B, et al.: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-2306. 10.1056/NEJMoa1811744

29. Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M: Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovasc Diabetol. 2019, 18:76. 10.1186/s12933-019-0877-2

30. Wanner C, Inzucchi SE, Lachin JM, et al.: Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2019, 380:2295-2306. 10.1056/NEJMoa1811744

31. Takashima H, Yoshida Y, Nagura C, et al.: Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial. Diab Vasc Dis Res. 2018, 15:469-472. 10.1177/1479164118782872

32. Ito H, Matsumoto S, Izutsu T, et al.: Different renoprotective effects of luseogliflozin depend on the renal function at the baseline in patients with type 2 diabetes: A retrospective study during 12 months before and after initiation. PLoS One. 2021, 16:e0248577. 10.1371/journal.pone.0248577

33. Pasternak B, Wintzell V, Melbye M, et al.: Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BML. 2020, 569:m1186. 10.1136/bmj.m1186

34. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ: Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011, 34:2015-2022. 10.2337/dc11-0606

35. Damman K, Biesselaar JC, Boorsma EM, et al.: Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020, 22:713-722. 10.1002/ejhf.1713

36. Fioretto P, Del Prato S, Buse JB, et al.: Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes Metab. 2018, 20:2532-2540. 10.1111/dob.13415

37. Jardine MJ, Zhou Z, Mahaffey KW, et al.: Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDEnCE randomized trial. J Am Soc Nephrol. 2020, 31:1128-1139. 10.1681/ASN.2019111168